Towards Healthcare Research & Consulting
U.S. Drug Screening Market
Updated Date: 08 June 2026   |   Report Code: 5839
[email protected] +1 804-441-9344
Download Sample Order Now

U.S. Drug Screening Market Powers Innovation In Point Of Care Testing Solutions

According to Rohan Patil, who specializes in healthcare and life sciences market intelligence with 5+ years of experience in market research and industry analysis, the U.S. Drug Screening Market is set for steady expansion, rising from USD 2.90 billion in 2026 to USD 4 billion by 2035 at a 2.7% CAGR. His analysis highlights strong segment leadership from drug screening services, urine-based testing, opioid detection, and workplace end users, alongside faster growth in oral fluid testing and rapid test devices. Regionally, the South & Midwest U.S. lead the market, while the West Coast shows the fastest growth momentum. He also identifies a consolidated competitive landscape dominated by Quest Diagnostics, Labcorp, Abbott, Thermo Fisher Scientific, and Roche.

Last Updated : 08 June 2026 Category: Healthcare Services Insight Code: 5839 Format: PDF / PPT / Excel

Content

Chapter 1: Introduction

  • Market Definition & Taxonomy
  • Research Objectives
  • Market Scope & Assumptions
  • Study Timeline (Historical, Base Year, Forecast Period)
  • Key Stakeholders Covered

Chapter 2: Research Methodology

  • Research Framework Overview
  • Market Size Estimation Methodology
    • Bottom-Up Approach
    • Top-Down Approach
  • Forecasting Model
    • Dependent Variables
    • Independent Variables
    • Key Assumptions & Weightages
  • Primary Research Insights
  • Secondary Data Sources
  • Data Validation & Triangulation

Chapter 3: Executive Summary

  • Global & Regional Overview (Value, CAGR)
  • Epidemiology Snapshot
  • Segmental Overview
  • Competition Key Snippets
  • Strategic Takeaways

Chapter 4: Market Catalysts, Constraints & Growth Levers

  • Market Dynamics
  • Market Drivers/Catalysts
    • Driver 1
    • Driver 2
  • Market Restraints
    • Restraint 1
    • Restraint 2
  • Market Opportunities
    • Opportunity 1
    • Opportunity 2
  • Market Trends
    • Trend 1
    • Trend 2
  • Impact Assessment of Drivers, Restraints, Opportunities & Trends (High, Mid, & Low)

Chapter 5: Value Added Intelligence

  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers: Low/Moderate/High
    • Bargaining Power of Buyers: Low/Moderate/High
    • Threat of New Entrants: Low/Moderate/High
    • Threat of Substitute: Low/Moderate/High
    • Competitive Rivalry: Low/Moderate/High
  • PESTEL Analysis
  • Ecosystem Analysis
  • Mapping of Key Players
  • Value Chain Analysis
  • Margin Analysis Across Value Chain
  • Macro & Micro Factors Impacting Market
  • Market Potential Evaluation, By Region
  • Epidemiology & Patient Pool Analysis
    • Disease Incidence & Prevalence
    • Target Patient Pool
      • Diagnosed Population
      • Service-Seeking Population
    • Patient Flow & Utilization Analysis
      • Patient Footfall
      • Admission Rates
      • Procedure Volume
    • Healthcare Infrastructure Analysis
      • Number of Facilities
        • Hospitals
        • Clinics
        • Diagnostic Centers
        • ASCs
      • Bed Capacity
        • Total Beds
        • ICU Beds
      • Facility Distribution
    • Operational Metrics Analysis
      • Bed Occupancy Rate (%)
      • Average Length of Stay (ALOS)
    • Service Pricing & Revenue Model
      • Pricing Analysis
        • Cost per Procedure
        • Cost per Consultation
        • Cost per Diagnostic Test
      • Revenue Streams
        • Inpatient Services
        • Outpatient Services
        • Ancillary Services
      • Workforce & Staffing Analysis
        • Healthcare Workforce
          • Physicians
          • Nurses
          • Technicians
        • Staff-to-Patient Ratios
        • Skill Gap Analysis
        • Labor Cost Structure
      • Scenario Analysis (Base / Optimistic / Pessimistic)
      • Risk Assessment & Sensitivity Analysis
      • Opportunity Analysis, By Region
      • Regulatory Analysis
      • Sustainability & ESG Insights
      • Business Models
      • Investment & Funding Landscape
      • Key Conferences and Events

Chapter 7: Segmental & Regional Analysis

      • U. S. Drug Screening Market Analysis
    • U. S. Drug Screening Market Analysis, By Product & Service, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U. S. Drug Screening Market Analysis, By Sample Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U. S. Drug Screening Market Analysis, By Drug Class Detected, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U. S. Drug Screening Market Analysis, By End User, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U. S. Drug Screening Market Analysis, By Technology, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis

Similar Analysis will be given for each country and each region

  • Canada
  • Mexico
  • Rest of North America

Europe

  • Western Europe
  • Germany
  • Italy
  • France
  • Spain
  • UK
  • Netherlands
  • Switzerland
  • Nordic Countries
  • Rest of Western Europe
  • Eastern Europe
  • Austria
  • Russia & Belarus
  • Poland
  • Türkiye
  • Rest of Eastern Europe

Asia Pacific

  • China
  • Taiwan
  • India
  • Japan
  • Vietnam
  • Australia and New Zealand
  • ASEAN Countries
  • South Korea
  • Rest of APAC

South America

  • Brazil
  • Argentina
  • Rest of South America

Middle East and Africa (MEA)

  • GCC Countries
  • South Africa
  • Egypt
  • Rest of MEA

Chapter 6: Competitive Insights

  • Competitive Analysis
    • Company Evaluation Matrix
      • Major Players
      • Mid-Sized Companies
      • Emerging Players/Start-Ups
    • Global Market Share Analysis, By Region, 2025 (%)
    • Key Player Positioning
    • Competitive Benchmarking
      • By Segment 1
      • By Segment 2
      • By Segment 3
    • Strategies of Key Players
    • Insight From the Horse’s Mouth

 

  • Company Profiles
    • Company 1
      • Company Name
      • Company Headquarters
      • Management Overview
        • Key C-Suite Executives
          • CEO
          • MD
          • Others
        • Employee Count
        • Business Strategy
          • Key Investments Made
          • Future Plans
          • R&D & Innovation Capabilities
          • Recent Developments
            • New Product Launch
            • Merger & Acquisitions
            • Partnerships & Collaborations
            • Market Expansion
            • Others
          • Service Portfolio
          • Facility Network
            • Number of Facilities
            • Bed Capacity
            • Facility Distribution
            • Expansion Pipeline
          • Key Financials (2022-2025)
            • Revenue By Segment
            • Revenue By Service
            • Revenue By Geography
            • Financial Matrix (Gross Profit Margins, Net Margins, etc.)
          • Key Clients
            • Client Company Name
            • Key Contact Person
            • Contact Details
          • Regulatory & Certification Expertise
          • SWOT Analysis

FAQ's

Answer : The U.S. drug screening market is valued at USD 2.9 billion in 2026 and is projected to reach USD 4 billion by 2035, growing steadily at a CAGR of 2.7%.

Answer : The U.S. drug screening market includes five segments such as by product & services, by sample type, by drug class detected, by end-user, and by technology.

Answer : Some key players include Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings (LabCorp), Abbott Laboratories (Abbott Toxicology), Alere Inc. (now part of Abbott), Thermo Fisher Scientific Inc., Orasure Technologies, Inc., etc.

Answer : Key trends include rising collaboration among key market players and growing demand from neighboring and lower-income countries.

Answer : Drug testing provides important information about the compounds included in drug samples. By using this information to completely understand what is in their substance or substances, PWUD may be able to make better usage decisions and reduce their chance of overdose.

Answer : The accuracy of urine and saliva tests depends on the time period in issue, since they are more effective at identifying recent usage.

Answer : Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions

Meet the Team

Rohan Patil is a seasoned market research professional with over 5+ years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

Learn more about Rohan Patil

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar